Goldhirsch, Aron2; Gelber, Richard D3; Piccart-Gebhart, Martine J3; de Azambuja, Evandro3; Procter, Marion3; Suter, Thomas M3; Jackisch, Christian3; Cameron, David3; Weber, Harald A3; Heinzmann, Dominik3; Dal Lago, Lissandra3; McFadden, Eleanor3; Dowsett, Mitch3; Untch, Michael3; Gianni, Luca3; Bell, Richard3; Köhne, Claus-Henning3; Vindevoghel, Anita3; Andersson, Michael1; Brunt, A Murray3; Otero-Reyes, Douglas3; Song, Santai3; Smith, Ian3; Leyland-Jones, Brian3; Baselga, Jose3
1 Onkologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark2 Department of Medicine, European Institute of Oncology, Milan, Italy. firstname.lastname@example.org unknown
an open-label, randomised controlled trial
Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.